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Abstract
Tolfenamic acid lowers the levels of the amyloid precursor protein (APP) and amyloid beta (Aβ)
when administered to C57BL/6 mice by lowering their transcriptional regulator specificity protein
1 (SP1). To determine whether changes upstream in the amyloidogenic pathway that forms Aβ
plaques would improve cognitive outcomes, we administered tolfenamic acid for 34 days to
hemizygous R1.40 transgenic mice. Following the characterization of cognitive deficits in these
mice, assessment of spatial learning and memory functions revealed that treatment with tolfenamic
acid attenuated long-term memory and working memory deficits, determined using Morris water
maze (MWM) and the Y-maze. These improvements occurred within a shorter period of exposure
than that seen with clinically approved drugs. Cognitive enhancement was accompanied by
reduction in the levels of the SP1 protein (but not mRNA), followed by lowering both the mRNA
and protein levels of APP, and subsequent Aβ levels. These findings provide evidence that
tolfenamic acid can disrupt the pathological processes associated with AD and are relevant to its
scheduled biomarker study in AD patients.
Keywords
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1. Introduction
Alzheimer’s disease (AD) represents the most prevalent neurodegenerative disease in the
elderly. During the course of the disease, memory, cognitive performance, and other daily
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activities are all impaired as a result of extensive neuronal loss (Berg, et al., 1993; Braak and
Braak, 1997; Nelson, et al., 2012). AD is characterized by the presence of neuropathological
deposits consisting of extracellular senile plaques of β-amyloid core and intraneuronal
neurofibrillary tangles (NFTs), especially in the cerebral cortex, hippocampus, subcortical
nuclei and amygdala (Selkoe, 2001; Reddy, et al., 2010; Ballard, et al., 2011; Harrington,
2012)
The amyloid precursor protein (APP) is processed by the beta-site APP-cleaving enzyme 1
(BACE1) and γ-secretase to generate various β-amyloid (Aβ) peptide isoforms that can
accumulate resulting in the formation of the insoluble aggregates of amyloid plaques (Shoji,
et al., 1992; Urbanc, et al., 1999; Querfurth and LaFerla, 2010; Zhang, et al., 2012). Aβ1-40
and Aβ1-42 are the major generated isoforms with Aβ1-42 found to be more aggregative
triggering amyloid plaque formation (Naslund, et al., 2000; Finder and Glockshuber, 2007).
Accumulation of Aβ into amyloid plaques initiates a pathological cascade resulting in
synaptic dysfunction and neuronal death that contributes to the neurodegeneration observed
in AD according to the amyloid hypothesis (Hardy and Higgins, 1992; Selkoe, 2001).
However, other studies suggest that Aβ soluble oligomers and aggregates are the toxic
species, and that in AD patients, soluble Aβ levels highly correlate with disease severity
markers (McLean, et al., 1999; Kroth, et al., 2012).
FDA-approved drugs for treatment of AD include four cholinesterase inhibitors and one N-
methyl-D-aspartate receptor antagonist. However, these medications are not disease-
modifying and they do not stop the progression of AD (Ozudogru and Lippa, 2012). Current
research focuses on interventions that target Aβ production and aggregation, and the
production of hyperphosphorylated tau (Roberson and Mucke, 2006; Gotz, et al., 2012;
Ozudogru and Lippa, 2012); however no therapeutic strategy has explored more upstream
interventions at the transcriptional level. Specifitcity protein 1 (SP1) co-activates the
transcription of APP, BACE1 and tau genes (Heicklen-Klein and Ginzburg, 2000;
Christensen, et al., 2004; Docagne, et al., 2004), and consequently changes in its levels can
alter the downstream pathways related to amyloidogensis (Basha, et al., 2005; Adwan, et al.,
2011) and tau (unpublished data) pathology. Tolfenamic acid, a non-steroidal anti-
inflammatory drug (NSAID), induces the degradation of SP1 protein (Abdelrahim, et al.,
2006) and data from our lab have shown that the treatment of wild type C57BL/6 mice with
tolfenamic acid lowered the levels of cerebral SP1 and the expression of AD-related Sp1
target genes such as APP (Adwan, et al., 2011).
Transgenic mouse models of AD are useful for elaborating mechanisms involved in the
development and progression of AD. In addition, they allow for testing of new therapies in
vivo to provide more accurate data for testing in human clinical trials (Hock and Lamb,
2001; Duff and Suleman, 2004). Our previous studies were conducted in wild type C57BL/6
mice that do not exhibit AD pathology and so we could not assess for cognitive function
improvement associated with an amyloidogenic pathway. Thus, we decided to examine the
ability of tolfenamic acid to lower AD proteins, including SP1, APP, and Aβ, and to
examine whether such reductions are commensurate with improvements in cognitive
functions in a mouse model of AD. Since the endogenous APP promoter is largely driven by
SP1 (Docagne, et al., 2004), we chose to study the effects of tolfenamic acid (which
degrades SP1), in the hemizygous R1.40 mice, a genomic-base transgenic mouse model that
harbors the Swedish mutation APPK670N/M671L, driven by the human APP promoter
(Lamb, et al., 1993).
Therefore, following the characterization of learning and memory impairment in female
hemizygous R1.40 transgenic mice, 5 and 50 mg/kg/day tolfenamic acid was administered
to female R1.40 mice aging between 14–21 months via oral gavage for 34 days and learning
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and memory functions were assessed in the Morris water maze (MWM) and the Y-maze. On
Day 35, mice were euthanized and AD associated proteins including SP1, APP and soluble
and insoluble Aβ1–40 and Aβ1–42 were assessed in the frontal cortex, which displays
extensive AD pathology in this animal model (Kulnane and Lamb, 2001; Lehman, et al.,
2003).
2. Methods
2.1. Animal model
The transgenic mouse model R1.40 was utilized for this study. The rational for choosing this
transgenic line relies on the fact that the mutant human APP gene is driven by its
endogenous human promoter unlike the majority of other transgenic lines, which utilize
hamster PrP or murine Thy-1 promoters (Hock and Lamb, 2001). The human promoter
region has numerous CpG boxes that SP1 binds to whilst activating gene expression. Thus
R1.40 is an ideal mouse model to conduct experiments on, as tolfenamic acid lowers SP1
and thus alters upstream transcriptional pathways of APP. These transgenic mice, B6.129-
Tg(APPSw)40btla/J, were obtained from Jackson laboratory (Bar Harbor, ME, USA) and
colonies of hemizygous and homozygous strains were established in-house. R1.40 is a
genomic-based transgenic mouse model that was developed by Bruce T. Lamb, it utilizes a
yeast artificial chromosome (YAC) that contains the full 400 kb human APP gene and
flanking sequence of approximately 250 kb to harbor the Swedish mutation APPK670N/
M671L, including the human transcriptional regulatory elements needed for proper spatial
and temporal expression (Reaume, et al., 1996; Lamb, et al., 1997; Hock and Lamb, 2001).
The developed hemizygous R1.40 line shows a significant increase in APP and Aβ
production as early as three months of age with Aβ plaque deposition occurring at 24–26
months of age compared to the wild type mice. Furthermore, the mnemonic deficits in R1.40
were similar to those observed in AD (Lamb, et al., 1999; Hock, et al., 2009).
In order to establish R1.40 transgenic mice colonies, mice were bred and genotyped in-
house at the University of Rhode Island. To ensure the accuracy of genotyping results, two
genotyping techniques were performed: standard PCR followed by gel electrophoresis on
1.5% agarose gel, and the TaqMan® allelic discrimination assay (Applied Biosystems,
Foster City, CA, USA, see supplementary data for details). Animals of mixed genotypes
were housed in standard mouse cages in the URI animal quarter rooms with a 12:12 hr light-
dark cycle (light on 6:00 AM, light off at 6:00 PM). Temperature was maintained at 22±2°C
with humidity levels of 55±5% and food and water available for mice ad libitum. The
University of Rhode Island Institutional Animal Care and Use Committee (IACUC)
approved all protocols including the breeding and genotyping methods. Animals were under
continuous supervision by a URI veterinarian during the entire study and during drug
administration.
2.2. Assessment of cognitive deficits in hemizygous R1.40 transgenic mice
In order to characterize memory and cognitive deficits in the hemizygous R1.40 transgenic
mouse model, behavioral testing in mazes that are reliant on the integrity of the
hippocampus and brain cortex was conducted using the MWM and spontaneous alternations
in the Y-maze. Preliminary studies showed cognitive deficits in both male and female mice
and the drug under study was active in both genders. In this study, we decided to use a
single gender to minimize any possible influence or interference that may be created due to
the use of mixed genders in the experiments. Thus, female hemizygous APP transgenic
(n=19) and female control wild type (n=18) groups of ages ranging between 9–20 months
were used.
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2.2.1. MWM—We have tested the mice in the hidden version of the MWM. In this task, the
mice had to locate the hidden platform by learning multiple spatial relationships between the
platform and the distal extra-maze cues (Vorhees and Williams, 2006; Gulinello, et al.,
2009; Laczo, et al., 2009). The apparatus consisted of a white 48″ diameter pool that is 30″
in height and was filled with water to a depth of 14″. The water was kept opaque by the
addition of white non-toxic liquid washable paint. The pool was surrounded by distinct fixed
visual cues that the animals used to navigate to reach the escape platform. A clear Plexiglas
platform 10 cm2 was kept submerged 0.5 cm below the surface of the water. The
temperature of the water was maintained at 25 ±2°C during all experiments in the water
maze. On Day 15 of tolfenamic acid administration, mice received a habituation trial in
which they were allowed to swim freely for 60 sec. On the following day and for a total of 8
days, mice received training sessions of 3 trials daily. The starting position for each trial was
randomly assigned between the four possible positions (one per quadrant) while the platform
position was fixed in each trial. Each animal was allowed to swim until they found the
immersed hidden platform or for a maximum duration of 60 sec. If the mouse failed to
locate the platform, it would be gently guided to sit on the platform for a maximum duration
of 30 sec. Mice were also left to sit on the platform for a maximum of 10 sec upon
successful trial. After completion of the 8 acquisition sessions, probe trials for up to 60 sec
on Day 1 and Day 11 following the last day of training were performed to assess long term
memory retention by studying the preference of the mice for the correct quadrant that
previously contained the hidden platform. The swim paths and latencies to locate the
platform and time spent in quadrants were videotaped and tracked with a computerized
video tracking system (ObjectScan, Clever Sys. Inc., Reston, VA, USA) and the resultant
data were analyzed.
2.2.2. Spontaneous alternation in the Y-maze—The spontaneous alternation ratio,
defined as the percentage of the number of arm entries different from the previous two
entries divided by the total arm entries minus two (King, et al., 1999; Hock, et al., 2009),
was measured. Testing was conducted in a white Y-maze with arms that were 12″ (long) by
3″ (wide) with 8″ high walls. Mice were placed into one of the Y-maze arms and were left
to explore the maze freely for 5 minutes. After each trial, the maze was cleaned with 70%
ethanol. Y-maze trials were videotaped and tracked with a computerized video tracking
system (ObjectScan, Clever Sys. Inc., Reston, VA, USA) and the data was analyzed.
2.3. Animal exposure to tolfenamic acid and behavioral testing
Tolfenamic acid was obtained from Sigma Aldrich (St. Louis, MO, USA) and female
hemizygous APP YAC R1.40 transgenic mice aged between 14–21 months were used to
examine the ability of tolfenamic acid to reduce the amyloidogenic load and to improve the
learning and memory deficits of the mice. From our initial published studies with tolfenamic
acid (Adwan, et al., 2011), we found that 5 and 50 mg/kg/day were the optimum low and
high doses capable to produce reductions in amyloidogenic proteins. We also found that a
treatment duration of 15 days was the minimum period required to show significant
reductions in APP and Aβ. Thus, on day 15 of drug administration, we started conducting
behavioral experiments and tolfenamic acid administration continued until the last day of the
behavioral studies. The animals were divided into three groups of similar age variation and
were administered tolfenamic acid daily via oral gavage for 34 days; one group was
administered 5 mg/kg/day tolfenamic acid in corn oil (n=6); the second group was
administered 50 mg/kg/day tolfenamic acid in corn oil (n=7) and the third group was
administered the corn oil vehicle, (n=6). After 14 days of dosing, mice were tested in the
MWM as described in section 2.2.1. On Day 33, mice were tested for spontaneous
alternation in the Y-maze as described in section 2.2.2. Finally, on Day 35, mice were
euthanized and brain tissue was extracted, dissected and stored at −80°C. Figure 1 provides
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a timeline for the experimental events involved in drug administration and behavioral
assessment.
2.4. Protein extraction and Western blot analysis
Brain cortices were homogenized with RIPA lysis buffer containing 10 mM Tris-HCl [pH
7.4], 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 1 mM EDTA, and 0.1% protease
inhibitor cocktail. The homogenates were centrifuged at 10,000 × g for 10 min at 4°C and
supernatants were collected. Protein levels were determined using the BCA kit (Pierce
Biotechnology, Inc., Rockford, IL, USA). Forty μg of total protein was separated on 8%
SDS polyacrylamide gel and then transferred onto polyvinylidiene diflouride (PVDF)
membranes (GE Healthcare, Piscataway, NJ, USA). Membranes were blocked using 5%
non-fat milk in TBST (Tris buffered saline + 0.5% Tween-20, pH 7.4) for 1 hr. Membranes
were then incubated overnight at 4°C with the specific antibody diluted in TBST for 1 hr
(1:2000 dilution of 6E10 for APP (Covance Research Products Inc., Dedham, MA, USA)
and 1:500 dilution of 1C6 for SP1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA). After
washing membranes 4 times with TBST, membranes were incubated for one hour with the
anti-mouse IRDye® 680 (Li-Cor Bioscience, Lincoln, NE) (1:5000) at room temperature.
After washing the membranes twice with TBST and once with TBS, the images were
developed using the Li-Cor Odyssey infrared imaging system (Li-Cor Bioscience, Lincoln,
NE, USA). The membranes were also re-probed for β-actin (Sigma Aldrich, St. Louis, MO,
USA) at a dilution of 1:2500 in TBST to obtain the APP/β-Actin ratio. The intensities of the
obtained Western blot bands were determined using Odyssey V1.2 software (Li-Cor
Bioscience, Lincoln, NE, USA).
2.5. RNA isolation, synthesis of cDNA and quantitative Real-Time PCR
RNA was isolated from cortical tissue following the TRIzol® Reagent method (Invitrogen,
Carlsbad, CA, USA), checked for integrity using NanoDrop 2000 Micro-Volume UV-Vis
Spectrophotometer (Thermo Scientific, Wilmington, DE, USA) and gel electrophoresis.
RNA was reverse transcribed to cDNA using the iScript™ Select cDNA Synthesis Kit
following manufacturer’s instructions (Bio-Rad, Hercules, CA, USA). About 1000ng of
RNA was diluted to 19.5μl with nuclease free water, then 3μl Oligo (dT) mix, 6μl 5x
iScript Select reaction mix, and 1.5μl of iScript reverse transcriptase was added. Samples
were incubated at 42°C for 90 min then at 85°C for 5 min to terminate the reaction. All
incubations were conducted using MJ Research MiniCycler™ PTC-150 (Bio-Rad, Hercules,
CA, USA). Primer pairs for Sp1, APP and β-actin were obtained from Invitrogen (Carlsbad,
CA, USA) as follows: Sp1 sense: 5′-CAA GCC CAA ACA ATC ACC TT-3′, and
antisense, 5′-CAA TGG GTG TGA GAG TGG TG-3′; APP sense: 5′-TGC AGC AGA
ACG GAT ATG AG-3′, and antisense: 5′-ACA CCG ATG GGT AGT GAA GC-3′; β-
actin sense: 5′-TGT TAC CAA CTG GGA CGA CA-3′, and antisense: 5′-TCT CAG CTG
TGG TGG TGA AG-3′. Each Real-Time PCR reaction mix contained 2μl of cDNA, 1μl of
each primer, 8.5μl nuclease free water and 12.5μl SYBR® Green PCR Master Mix (Applied
Biosystems, Foster City, CA, USA). Real-Time PCR was conducted using 7500 Real-Time
PCR System (Applied Biosystems, Foster City, CA, USA) following the standard protocol:
50°C for 2 min followed by 95°C for 10 min, then 40 cycles of 95°C for 15 sec and 60°C for
1 min. Results were analyzed using SDS software and expression data were reported relative
to β-actin mRNA using the 2−ΔΔCt method.
2.6. ELISA Aβ1–40 and Aβ1–42 Assay
Enzyme-linked immunosorbent assay (ELISA) using human Aβ1–40 and Aβ1–42 assay
IBL kits JP27713 and JP27711 determined Aβ levels, both soluble and insoluble fractions,
(Immuno-Biological Laboratories, Gunma, Japan). These kits are solid-phase sandwich
ELISA with two types of highly specific antibodies that are 100% reactive with mouse
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Aβ1-40 with a sensitivity of 5.00 pg/ml (JP27713), and 70% reactive with mouse Aβ1-42
with 4.03 pg/ml sensitivity (JP27711). The assay conditions were followed according to a
method described in the literature (Morishima-Kawashima, et al., 2000; Wu, et al., 2008).
The levels of Aβ in the test samples were calculated relative to the standard curve generated
on each plate.
2.7. Statistical analysis
Biochemical data are expressed as the mean ± the standard error of the mean (SEM).
Assessment of performance in MWM daily training sessions between the hemizygous R1.40
and the wild type groups was determined using repeated measure analysis of variance
(ANOVA) while probe trials differences between both groups was determined by a two-
tailed student t-test. The significance of differences between various treatment groups was
determined by repeated measure ANOVA and Tukey-Kramer multiple comparison a
posteriori analysis. All statistical analyses were conducted using GraphPad InStat 3 software
(GraphPad Software, La Jolla, CA, USA). Probability (p) value of <0.05 was considered
statistically significant.
3. Results
3.1. Overall safety and toxicity observations
Overt toxic effects of tolfenamic acid administration were not observed in these animals. No
changes in body weight were observed and treatment with tolfenamic acid did not result in
any abnormal behavior compared to non-exposed mice. Although the safety of tolfenamic
acid has been previously established, as it has been used in Europe for decades for
rheumatoid arthritis and for migraine, recent toxicity studies conducted by one of our
collaborators showed that chronic administration of tolfenamic acid of 50 mg/kg three times
a week for 6 weeks did not cause changes in hematocrit or hemoglobin in tolfenamic acid
exposed mice. In addition, histopathological analysis showed that acute and chronic
administration of tolfenamic acid did not produce adverse changes in gastric and intestinal
epithelia (available unpublished data).
3.2. Hemizygous R1.40 mice exhibit cognitive impairments when tested in the MWM and in
the Y-maze
Spatial navigation in the MWM is one type of test used to assess long-term memory
functions, which are usually impaired in AD. In the daily sessions which consisted of three
trials per day for a total of eight days, repeated measure ANOVA indicated no significant
difference in the performance, assessed by measuring escape latency, between the transgenic
group and the control wild type mice in this task (F(7,245) = 0.924, p > 0.05) (Fig. 2A).
However, probe trials that assessed the percent time in the correct quadrant that contained
the hidden platform showed that as the retention delay increased from Day 1 following the
last day of the daily training sessions to Day 11, the transgenic mice exhibited memory
impairment as they failed to remember the location of the hidden platform. As shown in
figure 2B, probe trials in Day 1 following the last day of daily training sessions showed no
significant difference between both groups (p > 0.1). However, after a longer delay on Day
11 following the last day of daily trainings sessions, the hemizygous R1.40 transgenic mice
significantly spent less time (Mean = 23%; SEM = 1.99%) compared to the control wild
type mice (Mean = 29.8%; SEM= 2.58%), p = 0.045 (Fig. 2B). In addition, ANOVA
analysis of target preference showed that both WT and R1.40 mice spent significantly more
time in the correct quadrant in the first probe trial. However, in the second probe trial, only
the WT group retained such significant target preference. The R1.40 mice group failed to
maintain target preference indicating memory impairment (See supplementary data).
Subaiea et al. Page 6
Neurobiol Aging. Author manuscript; available in PMC 2014 October 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Working memory function was assessed by measuring the spontaneous alternations in the
Y-maze. This task is based on the innate nature of the mice to visit arms that have not been
recently visited (King, et al., 1999; Hock, et al., 2009). Results revealed that hemizygous
transgenic R1.40 mice exhibited impaired working memory function as they had a
significantly lower spontaneous alternation ratio (Mean = 0.413; SEM = 0.021) than the
control wild type mice (Mean = 0.496; SEM = 0.019), p = 0.0047 (Fig. 3).
3.3. Treatment with tolfenamic acid reverses the cognitive deficits in hemizygous R1.40
mouse model
We determined above the presence of impaired behavioral performance in the hemizygous
R1.40 mice. This was manifested by a decline in the long-term memory and the working
memory functions as identified by poor retention of the spatial location of the platform in
the MWM and spontaneous alternations in the Y-maze, respectively.
We further examined the ability of a tolfenamic acid treatment of 5 and 50 mg/kg/day to
attenuate these learning and memory deficits in groups of female hemizygous R1.40
transgenic mice aging between 14–21 months. In the MWM task, there was a significant
effect of training as ANOVA analysis showed that the difference in escape latency between
the first to the last daily training sessions was statistically significant (F(7,144) = 7.833, p <
0.0001). Escape latency between the treatment and the vehicle groups showed no significant
differences in daily learning acquisition (Fig. 4A). However, ANOVA analysis indicated an
improvement in long-term memory retention in Day 11 probe trials (F(2,15) = 4.145, p =
0.0369) (Fig. 4B). The Tukey-Kramer HSD post-hoc test showed that the mice group treated
with 50 mg/kg/day tolfenamic acid exhibited a significant improvement (HSD = 3.12, p <
0.05), while the treatment with 5 mg/kg/day failed to reach significance (HSD = 0.71 p >
0.5) (Fig. 4B). Furthermore, ANOVA analysis of target preference indicated that mice
groups treated with 50 mg/kg/day spent significantly more time in the correct quadrant in
both probe trials compared to other groups indicating memory improvement (See
supplementary data for details).
Results from the ANOVA analysis of the spontaneous alternation ratio in the Y-maze
showed a significant improvement in working memory (F(2,15) = 4.479, p = 0.0298) (Fig.
5). The Tukey-Kramer HSD post-hoc test revealed a significant improvement with
tolfenamic acid treatment of 50 mg/kg/day (HSD = 4.139, p < 0.05), however, treatment
with 5 mg/kg/day did not reach significance (HSD = 1.30, p > 0.05) (Fig. 5)
3.4. Tolfenamic acid treatment lowers SP1 protein without altering Sp1 gene expression
The protein levels of cortical SP1 normalized to β-actin were analyzed by Western blot
following treatment with 0, 5 and 50 mg/kg/day for 34 days. ANOVA analysis revealed a
significant difference in SP1 protein levels (F(2.11) = 8.747, p = 0.0053) (Fig. 6A). The
Tukey-Kramer HSD post-hoc test indicated a significant decrease of SP1 after treatment
with 5 mg/kg/day tolfenamic acid (HSD = 4.145, p < 0.05, % change = − 43%) and after
treatment with 50 mg/kg/day tolfenamic acid (HSD = 5.712, p < 0.01, % change = − 52%)
(Fig. 6A).
Sp1 mRNA expression was evaluated for the different treatment groups. Analysis of Sp1
mRNA levels showed that treatment with tolfenamic acid did not alter the gene expression
of Sp1 (F(2,16) = 0.082, p = 0.922) (Fig. 6B).
3.5. Reduction of APP protein and mRNA following treatment with tolfenamic acid
Cortical APP normalized to β-actin was analyzed by Western blot following treatment with
5 and 50 mg/kg/day for 34 days or with vehicle. ANOVA revealed that APP levels were
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lowered significantly (F(2,9) = 8.377, p = 0.009) (Fig. 7A). The Tukey-Kramer HSD post-
hoc test indicated a significant decrease in APP after treatment with 5 mg/kg/day tolfenamic
acid (HSD = 4.877, p < 0.05, % change = − 30.3%) and 50 mg/kg/day tolfenamic acid (HSD
= 5.139, p < 0.05, % change = − 32.5%) (Fig. 7A).
In addition to analysis of APP protein levels, APP gene expression was evaluated from the
different treatment groups by Real-Time PCR. ANOVA analysis of APP mRNA levels
revealed a significant decrease in APP gene expression (F(2,15) = 5.238, p = 0.019) (Fig.
7B). The Tukey-Kramer HSD post-hoc test indicated a significant decrease of APP mRNA
after treatment with 5 mg/kg/day tolfenamic acid (HSD = 3.885, p < 0.05, % change = −
50.3%) and after treatment with 50 mg/kg/day tolfenamic acid (HSD = 4.039, p < 0.05, %
change = − 52.3%) (Fig. 7B). The lowering of APP was not associated with adverse effects
(Adwan, et al., 2011)
3.6. Tolfenamic acid lowers both soluble and insoluble Aβ1–40 and Aβ1–42 levels
We measured the levels of cortical Aβ1–40 and Aβ1–42 levels in the Tris-saline-soluble and
in the insoluble fraction using IBL ELISA kits as described in the methods section
(Morishima-Kawashima, et al., 2000). ANOVA analysis showed that there was a significant
reduction in soluble Aβ1–40 fraction (F(2,14) = 3.89, p = 0.04) (Fig. 8A) and the insoluble
Aβ1–40 fraction (F(2,14) = 4.95, p = 0.02) (Fig. 8B). The Tukey-Kramer HSD post-hoc test
indicated a significant decrease in soluble Aβ1–40 after treatment with 50 mg/kg/day (HSD =
3.91, p < 0.05, % change = − 30.1%), however, the reduction in soluble Aβ1–40 after
treatment with 5 mg/kg/day did not reach significance (HSD = 2.55, p > 0.05, % change = −
21.3%) (Fig. 8A). Multiple group comparison showed a significant decrease in the insoluble
Aβ1–40 fraction after treatment with both 5 mg/kg/day (HSD = 3.73, p < 0.05, % change = −
35.2%) and 50 mg/kg/day tolfenamic acid (HSD = 3.97, < 0.05, % change = − 37.4%) (Fig.
8B).
Also, ANOVA analysis showed a significant decrease in soluble Aβ1–42 fraction (F(2,14) =
6.174, p = 0.012) (Fig. 8C) and the insoluble Aβ1–42 fraction (F(2,14) = 6.343, p = 0.011)
(Fig. 8D). The Tukey-Kramer HSD post-hoc test indicated a significant decrease in soluble
Aβ1–42 after tolfenamic acid treatment with 5 mg/kg/day (HSD = 4.18, p < 0.05, % change =
− 22.3%) and after treatment with 50 mg/kg/day (HSD = 4.518, p < 0.05, % change = −
24.9%) (Fig. 8C). Similarly, multiple group comparison showed a significant decrease in the
insoluble Aβ1–42 fraction after treatment with 5 mg/kg/day (HSD = 4.72, p < 0.05, % change
= − 31.8%) and 50 mg/kg/day (HSD = 4.79, < 0.05, % change = − 37.7%) (Fig. 8D).
We also observed that 5 and 50 mg/kg/day tolfenamic acid treatment reduced total Aβ1-42/
Aβ1-40 ratio −16.3% and −19.9%, respectively. However, this reduction in Aβ1-42/Aβ1-40
did not reach statistical significance (F(2.14) = 1.788, p = 0.203).
4. Discussion
Over the last two decades, more evidence has been garnered regarding the association
between chronic NSAIDs intake and up to 80% reduction in risk of AD incidence, slowing
of disease progression, and reduction of microglial activation (Andersen, et al., 1995;
McGeer, et al., 1996; Stewart, et al., 1997; in t’ Veld, et al., 2001; Lindsay, et al., 2002;
Zandi, et al., 2002; Etminan, et al., 2003; Vlad, et al., 2008; Cote, et al., 2012). Several
mechanisms have been proposed to explain how NSAIDs could exert their effects on AD
independent of their COX inhibitory pathways. Certain NSAIDs including indomethacin,
fulfinamic acid, ibuprofen and fenoprofen are agonists for the nuclear transcriptional
regulator peroxisome proliferator-activated receptor-γ (PPARγ) (Lehmann, et al., 1997;
Heneka, et al., 2011) which has been reported to be reduced in AD brains (Sastre, et al.,
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2006). PPARγ activation results in a reduction in the levels of Aβ-induced proinflammatory
response of microglia and monocytes, and promotes Aβ clearance by astrocytes and
microglia (Matsuo, et al., 1996; Combs, et al., 2000; Daynes and Jones, 2002; Yue and
Mazzone, 2009; Mandrekar-Colucci, et al., 2012). In addition, a PPARγ responsive element
(PPRE) has been identified in the BACE1 gene promoter that is repressed by PPARγ
binding resulting in a decrease in BACE1 expression (Sastre, et al., 2003; Sastre, et al.,
2006). Weggen et al., reported that a subset of NSAIDs specifically lower Aβ1-42 that was
accompanied by a parallel increase in Aβ1-38 suggesting a minor γ-secretase modulatory
effect without alteration of the Notch pathway (Weggen, et al., 2001). The specific Aβ1-42
inhibition by that subset of NSAIDs was further studied by Zhou et al., who concluded that
the involvement of Rho-Rock pathway in regulating APP processing, and inhibition of Rho
activity by specific NSAIDs could preferentially reduce Aβ1-42 (Zhou, et al., 2003).
Tolfenamic acid, of all other NSAIDs, has the unique mechanism of inducing the
proteasome dependent degradation of SP transcription factors including SP1, SP3 and SP4
and thereby, decreasing the expression of vascular endothelial growth factors (VEGF)
(Abdelrahim, et al., 2006), which is involved in tumor progression and metastases. Because
of its SP degradation effects, tolfenamic acid has been studied as a therapeutic agent for
cancer and research has confirmed its antitumor effects (Abdelrahim, et al., 2006; Konduri,
et al., 2009; Basha, et al., 2011; Colon, et al., 2011).
Sp1 involvement in AD has been researched and it was found that its expression was
elevated in the frontal cortex of AD brains as well as in the brains of transgenic mouse
models of AD (Santpere, et al., 2006; Citron, et al., 2008). The elevation of Sp1 was
accompanied by an increase in COX-2, another Sp1 target gene, suggesting interplay
between inflammatory processes and Sp1 driven gene expression (Citron, et al., 2008). Sp1
binds to 5′-GGGGCGGGGC-rich promoter genes such as APP and BACE1 genes, which
are involved in AD pathology, and Sp1 overexpression leads to induction of their protein
expression (Cai, et al., 2001; Christensen, et al., 2004; Citron, et al., 2008). We have
reported that silencing of Sp1 gene by siRNA resulted in 70% decrease in the
responsiveness of the human APP promoter (Basha, et al., 2005). Also, we have
demonstrated the co-localization of APP, Sp1 and Aβ in various regions of the brain (Brock,
et al., 2008). Thus, we proposed the hypothesis that tolfenamic acid could interrupt the de
novo synthesis of APP and consequently, alter the downstream levels of Aβ. This hypothesis
was confirmed when oral treatment with tolfenamic acid resulted in degradation of SP1
which was accompanied by a reduction in cortical and hippocampal APP gene expression
and protein, and Aβ peptide levels (Adwan, et al., 2011). This was further supported by
measurements which demonstrated the presence of tolfenamic acid in the brain following IV
administration (Subaiea, et al., 2011).
In the present study, we demonstrate that hemizygous R1.40 transgenic mice exhibit
cognitive deficits upon assessment of their working memory and long-term memory
retention even before the reported age of 24–26 months at which hemizygous R1.40 start to
suffer extensive β-amyloid deposition (Lamb et al., 1999). Hemizygous R1.40 mice start to
exhibit 7–8 times more Aβ1-42 levels compared to wild types as early as 3–4 months of age
(Lamb, et al., 1999). Thus, mice were studied at ages where there is a great increase in Aβ
levels in the brain prior to plaque depositions. Spatial learning was assessed in the hidden
version of the MWM and we found that the transgenic mice were able to learn to escape to
the hidden platform in the daily training sessions (Fig. 2A). However, they exhibited
memory retention impairments in the probe trials as they failed to retain the spatial location
of the hidden platform with increased delay (Fig. 2B, Day 11). Working memory assessed in
the Y-maze was impaired in these mice as demonstrated by numerous alternation errors and
a lower alternation ratio compared to the wild type control group (Fig. 3). It has been
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proposed that recent spatial memory is hippocampal-dependent, while remote spatial
memory is dependent on the integrity of the medial prefrontal cortex (King, et al., 1999;
Frankland and Bontempi, 2005; Teixeira, et al., 2006). In turn, working memory assessed in
the Y-maze is hippocampal and cortical-dependent (Lalonde, 2002). That, together with the
findings that the R1.40 mouse model exhibits extensive amyloid deposition in the cortical
region compared to that observed in the hippocampal formation (Hock, et al., 2009), may
explain the observed results.
We report here that short-term tolfenamic acid administration was able to improve the
mnemonic deficits observed in hemizygous R1.40. We found that (Lamb, et al., 1999) 50
mg/kg/day tolfenamic acid was able to reverse the long-term memory retention deficits seen
in delayed probe trials of the MWM experiment (Fig. 4B). In addition, the 50 mg/kg/day
treatment group showed significant improvement in the Y-maze with less error in
spontaneous alternations (Fig. 5). However, the short-term treatment with 5 mg/kg/day
showed only modest effects in reversing the memory deficits in these mice. Analysis of
amyloid pathology markers indicated that both treatment regimens, 5 and 50 mg/kg/day,
were able to significantly lower the protein level of SP1 without altering its gene expression
indicating that the decrease in SP1 protein levels is not due to a change in its de novo
synthesis but is rather at the post-translational level (Fig. 6A and 6B). Those results were
similar to our previous findings in the C57BL/6 treated with tolfenamic acid (Adwan, et al.,
2011). In addition, both tolfenamic acid doses significantly reduced the protein levels of
APP and its gene expression (Fig. 7A and 7B). Furthermore, levels of the soluble and
insoluble Aβ1–40 and Aβ1–42 were reduced by tolfenamic acid with a trend toward lowering
the insoluble fractions of Aβ more than that of the soluble fraction (Fig. 8). It is possible that
tolfenamic acid may aid in clearance of insoluble Aβ by a PPARγ activation mechanism,
however, it is not clear yet if tolfenamic acid activates PPARγ as certain other NSAIDs do.
While tolfenamic acid was effective in lowering the amyloidogenic proteins with both doses,
we observed dose-dependent improvement in the cognitive deficits. Whether longer period
of treatment with low dose tolfenamic acid could result in significant improvements in
cognitive function is yet to be studied. However, it is essential to mention that tolfenamic
acid produced behavioral improvements after a rather short-term treatment period compared
to other FDA approved AD drugs and NSAIDs. For example, APP23 transgenic mice
treated with 0.58 mg/kg/day donepezil, an FDA-approved anticholinesterase drug for AD,
showed improved performance in MWM after two months of treatment (Van Dam, et al.,
2008). In addition, memantine, another FDA-approved drug for use in moderate to severe
AD, has shown to improve cognition in 3x TG-AD mice after three months of treatment
(Martinez-Coria, et al., 2010). Also, triple transgenic mice (APPswe, PS1M146V and
tauP301L) exhibited improved cognitive functions after treatment with ibuprofen for six
months (McKee, et al., 2008).
Many of the anti amyloid drugs that failed in clinical trials were anti-Aβ monoclonal
antibodies, γ-secretase inhibitors, BACE1 inhibitors or certain NSAIDs that do not lower
SP1 (Herrmann, et al., 2011; Ozudogru and Lippa, 2012). This might be either due to lack of
efficacy or ensuing adverse effects. The main targets of these drugs were proteins involved
at the end stage of the amyloidogenic pathway. Tolfenamic acid interferes with
transcriptional pathways associated with AD-related genes and thus it acts at upstream
pathways that can have impacts on downstream events and is not dependent on protein
events at the end of the amyloidogenic pathways. Thus, it may hold better promise for
success.
In conclusion, tolfenamic acid is unique among other NSAIDs in its ability to inhibit SP1
and thus interrupt APP de novo synthesis and its Aβ products. In this study, we
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demonstrated that administration of 50 mg/kg/day for 34 days of tolfenamic acid reversed
the cognitive deficits in hemizygous R1.40 transgenic mice. Consistent with our previous
published findings in C57BL/6 mice, SP1, the amyloidogenic levels of APP and soluble and
insoluble Aβ1–40 and Aβ1–42 were markedly lowered by tolfenamic acid in an AD
transgenic mice. These data provide further evidence that tolfenamic acid is a promising
therapeutic agent as a repurposed AD drug acting through an alternative mechanism and
should benefit the scheduled clinical trials of this drug.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. A timeline of tolfenamic acid administration and behavioral assessment
Mice were administered tolfenamic acid daily for 34 days. Behavioral testing in the MWM
began on the 15th day of dosing with daily training sessions that lasted until the 23rd day of
the study. On the 24th day of dosing, we conducted the first session of probe trials (Day 1)
and then we performed a second session of probe trials on the 34th of dosing (Day 11), to
assess for long-term memory retention. Trials for the spontaneous alternations in the Y-maze
were conducted on the 33rd day of dosing as well. Animals were euthanized on the 35th day
of the study and brain tissue was dissected, collected and stored in the −80°C freezer.
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Fig. 2. Memory impairments in hemizygous APP YAC transgenic mice, line R1.40, assessed by
the swimming task in the MWM
A) Acquisition patterns during daily training; B) Probe trials for long-term memory
retention on Days 1 and 11 following acquisition-training trials. “*” indicates that the values
are significantly different from control, as determined by a Student’s t-test (p<0.05).
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Fig. 3. Working memory impairments in hemizygous APP YAC transgenic, line R1.40 mice
Mice were examined for working memory function assessed by measuring the spontaneous
alternation ratio in the Y-maze. “**” Indicates that the values are significantly different from
control, as determined by a Student’s t-test (p<0.01)
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Fig. 4. The administration of tolfenamic acid to hemizygous APP YAC R1.40 mice improves
spatial memory
Tolfenamic acid was administered by oral gavage daily for 34 days. See the methods section
for details. A) Acquisition patterns during daily training trials of 5 mg/kg/day, 50 mg/kg/day
and vehicle groups; B) Probe trials assessing the long-term memory retention on Days 1 and
11 following acquisition training trials. “*” Indicates that values are significantly different
from vehicle, as determined by one-way ANOVA analysis with Tukey-Kramer post-hoc test
to compare all pairs of columns (p<0.05), obtained using GraphPad InStat 3 software.
Vehicle n=6; 5 mg/kg/day n=6; 50 mg/kg/day n=7.
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Fig. 5. Working memory improvement in hemizygous APP YAC transgenic mice, line R1.40,
after administration of tolfenamic acid assessed by spontaneous alternations in the Y-maze
Tolfenamic acid was administered by oral gavage daily for 34 days. See the methods section
for details. “*” Indicates that values are significantly different from vehicle control, as
determined by one-way ANOVA analysis with Tukey-Kramer post-hoc test to compare all
pairs of columns (p<0.05), obtained using GraphPad InStat 3 software. Vehicle n=6; 5 mg/
kg/day n=6; 50 mg/kg/day n=7.
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Fig. 6. Reduction of SP1 protein levels in the brain after treatment with tolfenamic acid
Tolfenamic acid was administered by oral gavage daily for 34 days. See the methods section
for details. A) Western blot analysis of cortical SP1 levels as a ratio of the house-keeping
protein β-actin after treatment with 5 and 50 mg/kg/day of tolfenamic acid for 34 days. B)
Cortical Sp1 mRNA levels determined by Real-Time PCR. “*” Indicates that values are
significantly different from vehicle, as determined by one-way ANOVA analysis with
Tukey-Kramer post-hoc test to compare all pairs of columns (*p<0.05, **p<0.01), obtained
using GraphPad InStat 3 software.
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Fig. 7. Reduction of amyloid precursor protein (APP) levels in the brain after treatment with
tolfenamic acid
Tolfenamic acid was administered by oral gavage daily for 34 days. See the methods section
for details. A) Western blot analysis of cortical APP levels as a ratio of the house keeping
protein β-actin after treatment with 5 and 50 mg/kg/day of tolfenamic acid for 34 days; B)
Cortical APP mRNA determined by Real-Time PCR. “*” Indicates that values are
significantly different from vehicle, as determined by one-way ANOVA analysis with
Tukey-Kramer post-hoc test to compare all pairs of columns (p<0.05), obtained using
GraphPad InStat 3 software.
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Fig. 8. Reduction of soluble and insoluble Aβ1-40 and Aβ1-42 levels in the brain after treatment
with tolfenamic acid
Tolfenamic acid was administered by oral gavage daily for 34 days. See the methods section
for details. ELISA quantified Aβ levels in the cortices of mice treated with 5 and 50 mg/kg/
day of tolfenamic acid for 34 days. A) Soluble Aβ1-40; B) Insoluble Aβ1-40; C) Soluble
Aβ1-42 and D) Insoluble Aβ1-42 levels. “*” Indicates that values are significantly different
from vehicle, as determined one-way ANOVA analysis with Tukey-Kramer post-hoc test to
compare all pairs of columns (p<0.05), obtained using GraphPad InStat 3 software.
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